Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of European patent No. 3,258,943 for AllocetraTM, enhancing its intellectual property portfolio. This patent covers a combination immune therapy aimed at controlling cytokine storms associated with CAR-T therapies for cancer. CEO Oren Hershkovitz expressed satisfaction with the patent grant in Europe, reinforcing the potential of Allocetra in cancer treatment. Allocetra is designed to reprogram macrophages to address severe conditions like sepsis, COVID-19, and solid tumors.

Positive

• Issuance of European patent No. 3,258,943 for AllocetraTM strengthens intellectual property protection.
• AllocetraTM targets unmet medical needs in severe diseases, enhancing its market potential.

Negative

• None.

Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) --  – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the European Patent Office has issued European patent No. 3,258,943 covering Allocetra^TM, the Company’s immunotherapy product candidate. The new patent’s title is “COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT”, and is expected to provide added intellectual property protection for therapeutic compositions of Allocetra^TMand CAR-T immunotherapies for inhibition or reduction ofcytokine storms associated with CAR-T therapies for cancer.

Oren Hershkovitz, PhD, CEO of Enlivex, stated, “We are pleased to have this patent granted in Europe, which adds to existing Allocetra^TM patents in various countries around the world. Specifically, this new patent further strengthens our existing intellectual property portfolio covering the use of Allocetra^TM for cancer therapy.”

Allocetra^TM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra^TM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.

ABOUT ENLIVEX

Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra^TM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

FAQ

What is the significance of the European patent issuance for ENLV's AllocetraTM?

The European patent No. 3,258,943 enhances ENLV's intellectual property portfolio, protecting its combination immunotherapy targeting cytokine storms in cancer.

How does AllocetraTM work in treating severe diseases?

AllocetraTM reprograms macrophages into their homeostatic state, potentially improving conditions like sepsis, COVID-19, and solid tumors.

Who announced the European patent for AllocetraTM?

Enlivex Therapeutics announced the patent issuance on June 15, 2021.

What diseases does AllocetraTM target?

AllocetraTM targets severe conditions including sepsis, COVID-19, and solid tumors.

What did the CEO of Enlivex say about the patent grant?

CEO Oren Hershkovitz expressed pleasure over the patent grant, emphasizing its role in strengthening their IP portfolio.